- Home
- LILA vs ADRX Comparison
LILA vs ADRX Comparison
Compare LILA & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILA | ADRX |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | LILA | ADRX |
|---|---|---|
| Price | $8.40 | $16.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $10.55 | ★ $34.25 |
| AVG Volume (30 Days) | 292.8K | ★ 429.1K |
| Earning Date | 11-04-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,442,200,000.00 | N/A |
| Revenue This Year | $0.92 | $72.35 |
| Revenue Next Year | $3.13 | $570.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.77 | $16.61 |
| 52 Week High | $9.04 | $19.57 |
Technical Indicators
Market Signals| Indicator | LILA | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 35.12 |
| Support Level | $8.28 | N/A |
| Resistance Level | $8.84 | $19.01 |
| Average True Range (ATR) | 0.26 | 1.20 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 81.93 | 11.74 |
Price Performance
Historical ComparisonAbout LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.